DERM Dermira Inc.

18.76
-0.04  -0%
Previous Close 18.8
Open 18.81
Price To Book 69.48
Market Cap 1,026,081,295
Shares 54,695,165
Volume 923,329
Short Ratio
Av. Daily Volume 2,663,049
Stock charts supplied by TradingView

NewsSee all news

  1. Lilly Announces Agreement to Acquire Dermira

    INDIANAPOLIS and MENLO PARK, Calif., Jan. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Dermira, Inc. (NASDAQ:DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per

  2. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  3. Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  4. Dermira to Participate in December Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  5. Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference

    - New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab's role in inhibiting itch signals in atopic dermatitis - Lebrikizumab Phase 3 program is currently enrolling adult

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 data released March 5, 2018 - failed to meet all co-primary endpoints.
Olumacostat glasaretil (DRM01)
Acne
Approval announced June 29, 2018.
Glycopyrronium tosylate
Primary axillary hyperhidrosis
Phase 3 trial initiation announced October 9, 2019. Top-line data due 1H 2021.
Lebrikizumab
Atopic Dermatitis
Proof of concept initiation announced February 22, 2019.
QBREXZA (glycopyrronium)
Primary palmar hyperhidrosis

Latest News

  1. Lilly Announces Agreement to Acquire Dermira

    INDIANAPOLIS and MENLO PARK, Calif., Jan. 10, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Dermira, Inc. (NASDAQ:DERM) today announced a definitive agreement for Lilly to acquire Dermira for $18.75 per

  2. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  3. Dermira Receives Fast Track Designation from FDA for Lebrikizumab for the Treatment of Atopic Dermatitis

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  4. Dermira to Participate in December Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  5. Dermira Presents New Scientific Research Findings from the Lebrikizumab Program at Leading International Itch Conference

    - New findings in human sensory neurons highlight role of IL-13 in amplifying itch and lebrikizumab's role in inhibiting itch signals in atopic dermatitis - Lebrikizumab Phase 3 program is currently enrolling adult

  6. Dermira Elects Halley E. Gilbert to its Board of Directors

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  7. Dermira to Participate in the Guggenheim Healthcare Talks Idea Forum, Neuro/Immunology Day

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  8. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  9. Dermira Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    - QBREXZA® (glycopyrronium) cloth net product sales of $10.2M - Phase 3 lebrikizumab program initiated in adult and adolescent patients with moderate-to-severe atopic dermatitis - Conference call today at 1:30 p.m.

  10. Dermira to Report Third Quarter 2019 Results and Host Conference Call on Tuesday, November 5, 2019

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of people living with chronic skin

  11. Dermira to Present Data from Phase 2b Study of Lebrikizumab in Patients with Atopic Dermatitis at Fall Clinical Dermatology Conference

    - Detailed primary results of lebrikizumab Phase 2b study to be presented at the Fall Clinical Dermatology Conference - Data reflect potential of lebrikizumab to offer best-in-disease combination of safety, efficacy,

  12. Dermira Announces Initiation of Phase 3 Program Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis

    - Two identical Phase 3 monotherapy studies expected to enroll a total of approximately 800 adult and adolescent patients ages 12 and older - Topline results from the 16-week induction period expected in the first

  13. Dermira Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  14. Dermira to Participate in the 2019 Cantor Global Healthcare Conference

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin

  15. Dermira to Participate in Upcoming Investor Conferences

    Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin